It has been clearly demonstrated that in endemic areas, improving the vitamin A status of children aged six months to five years can substantially reduce their risk of mortality and severe morbidity. This paper reviews the potential benefits of improving vitamin A status during the first six months of life by either supplementing the infant or indirectly by supplementing the mother, in order to increase the vitamin A content of her breastmilk. This focus is important, since a large proportion of childhood deaths occur before six months of age. Also, whether or not supplementation has a direct benefit during the first six months of life, it could have an indirect benefit later in life if it ensures that the infant enters the second six months of life with improved vitamin A status. It might thus lead to a reduced risk of mortality in later childhood. In particular, this review evaluates the evidence concerning the health benefits.
Introduction
Vitamin A deficiency has been identified by the World Health Organization (WHO) as a problem of public health importance in over 60 countries. About 250 million children are estimated to be at risk for this deficiency [1] . Several large-scale field trials have clearly demonstrated that in endemic areas, improving the vitamin A status of children can substantially reduce their risk of mortality and severe morbidity [2] . The vast majority of children recruited in these trials were aged six months to five years. It is thus in this age group that the impact has been demonstrated; on average, supplementation has been found to reduce mortality by 23% [2] .
This review focuses on the first six months of life. It examines strategies to improve the vitamin A status of the young infant and the potential health benefits of so doing. This focus is important for two main reasons. First, a large proportion of childhood deaths occurs before six months of age. It is thus important to understand whether the efficacy of vitamin A supplementation extends to the younger infant. Second, whether or not supplementation has a direct benefit during the first six months of life, it could have an indirect benefit later in life if it ensures that the infant enters the second six months of life with improved vitamin A status. It might thus lead to a reduced risk of mortality in later childhood.
Supplementation strategies
Improved vitamin A status of the young infant can potentially be achieved either directly, by supplementing the infant, or indirectly, by supplementing the lactating mother in order to increase the vitamin A content of her breastmilk and thus provide additional vitamin A to the breastfed infant.
This review evaluates the evidence concerning health benefits for the following vitamin A supplementation strategies: Maternal supplementation » Large dose in the first few weeks after delivery » Regular small doses throughout lactation Infant supplementation » Supplementation of newborns with 50,000 IU » Periodic supplementation of young infant with 50,000 IU » Immunization-linked supplements delivered at each of the contacts for diphtheria-polio-tetanus immunizations. The recommended scheduled for these is 6, 10, and 14 weeks of age
Combined maternal and infant supplementation
The evidence concerning potential health impact for the child is discussed for each of the three strategy approaches in the following three sections. The main
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findings are summarized in table 1, which lists the related randomized, double-blind, placebo-controlled trials. The results are shown separately as impacts on the vitamin A status of mothers, on vitamin A status of the infants, and on infant health. The review then seeks to draw on the presented evidence to discuss what might be recommended approaches for vitamin A supplementation during the first six months of life, summarizing what is known and highlighting any important gaps in knowledge. In so doing, it examines the potential role of linking supplements to immunization programs, which have established a delivery system that reaches a large proportion of children in areas where vitamin A deficiency is widespread.
Benefi ts of maternal supplementation
Three supplementation trials have been conducted that included maternal supplementation (table 1) . The first, in Indonesia [3] , evaluated a single large dose of vitamin A, equivalent to 300,000 IU given at one to three weeks postpartum, against a placebo. The second trial in Bangladesh [4] had three groups who received two different supplementation strategies and a placebo. All mothers were enrolled at one to three weeks postpartum and given an initial dose. They were then followed and given daily supplements until nine months postpartum. Mothers in the first intervention group received one large dose of 200,000 IU of vitamin A, followed by daily placebo doses until nine months postpartum. Those in the second intervention group received a single placebo dose followed by daily doses of 7.8 mg of β-carotene throughout. This was designed to approximate one US recommended dietary allowance (RDA) of vitamin A for lactating women in the first six months postpartum. Mothers in the control group received placebo doses at enrollment and throughout.
The third trial [9] , a multicenter study carried out in Ghana, India, and Peru, evaluated a single large maternal dose of 200,000 IU given between 18 and 42 days postpartum combined with infant supplements of 25,000 IU delivered alongside the diphtheria, pertussis, and tetanus (DPT)/polio immunizations.
The trials in Indonesia and Bangladesh each involved a total of just 150 to 200 mother-infant pairs and were designed to evaluate the impact on both the mothers' and the infants' vitamin A status. The multicenter trial involved more than 8,000 mother-infant pairs and also gathered data on morbidity and mortality; vitamin A status was evaluated on a subsample.
Impact on maternal vitamin A status
The main results concerning the impact on maternal vitamin A status are presented in figure 1 for each of the three trials and are summarized in table 1. Three different indicators have been used for maternal vitamin A status: serum retinol concentration, modified relative dose response (MRDR) to provide an assessment of the adequacy of liver stores, and breastmilk retinol concentration. An impact on the latter is the most relevant for assessing whether maternal supplementation is likely to lead to benefits for the breastfed infant.
In the Indonesian trial, breastmilk retinol was compared between vitamin A and placebo groups at baseline (before dosing at one to three weeks postpartum) and then at each month of age until eight months. At baseline, the mean breastmilk retinol concentration was lower in the vitamin A group than in the placebo group: 2.30 ± 1.42 µmol/L (n = 70), as compared with 2.69 ± 1.53 µmol/L (n = 66). The frequency of mothers with breastmilk concentrations below the 1.05 µmol/L cutoff was also marginally higher in the vitamin A group (10% vs 8%). At each subsequent point in time, supplementation raised breastmilk retinol concentrations by 0.48 to 1.18 µmol/L higher than the placebo group. At one month of age, shortly after supplementation, only one mother in the vitamin A group had a breastmilk concentration below 1.05 µmol/L, compared with 16 mothers (24%) in the placebo group (p < .0001). At all subsequent times, the frequency of breastmilk concentrations below 1.05 µmol/L was significantly lower for mothers in the vitamin A group. At eight months, the difference was still substantial: 16% as compared with 28%.
This sustained impact of supplementation on breastmilk retinol concentration was not replicated in either of the other two trials. The Bangladesh trial involved a similar number of mothers in each group; it also included a third group receiving daily doses of β-carotene. The breastmilk vitamin A concentration was expressed both per volume and per gram of milk fat, and was analyzed by comparing means and by comparing percentages below cutoff values. Similar results were found in all cases [4] . The percentages below 1.05 µmol/L are shown in figure 1B . At baseline, values were not statistically significantly different between the three groups. At three months, the vitamin A group showed a benefit as compared with the placebo group (57% vs 79%, p < .01), but this benefit had disappeared by six months. Daily supplementation with β-carotene had no impact on breastmilk concentrations at three months and six months, but appeared better than the placebo at nine months, when the percentage below 1.05 µmol/L was 63% as compared with 80% (p < .05).
The multicenter trial assessed breastmilk vitamin A concentration for a random subsample of approximately 1,500 mothers in each of the two trial groups at enrollment. Three different subsamples of these were selected to be reassessed at two, six, and nine months, giving between 280 and 340 measurements per group at each follow-up. The impact of vitamin A was apparent at two months (21.4% vs 27.8%, p = .06) and most marked at six months (30.0% vs 40.7%, p = .004), but had disappeared by nine months (fig. 1C ). When data were analyzed separately by country (table 2) , it can be seen that in India, where the percentage of women with low breastmilk retinol concentration was highest, the impact of vitamin A supplementation displayed its largest impact much earlier at two months.
It is worth noting that at baseline, about four times as many mothers in the Bangladesh trial as in the Indonesian trial had a breastmilk retinol concentration below the 1.05 µmol/L cutoff. In fact, percentages even at baseline in Bangladesh were higher than at eight months in Indonesia. By three months, this percentage exceeded 50% in all groups. Thus, the population was considerably vitamin A deficient. In addition, it should be noted that the vitamin A dose used was 300,000 IU in the Indonesian trial, as compared with 200,000 IU in the other two. The Indonesia and Bangladesh trials also assessed showed an inconsistent impact on liver stores; these were improved at three months and at nine months, but not at six months.
Impact on the infant's vitamin A status
The Indonesia and Bangladesh trials both included an assessment of the impact on the infant's vitamin A status at six months of age (tables 1-3). In the Indonesian trial, the investigators used a cutoff of <0.52 µmol/L to calculate the prevalence of low serum retinol; this is midway between the two more usual cutoffs of <0.35 µmol/L (severe deficiency) and <0.70 µmol/L (moderate deficiency), generally adopted as standards for young children. Using these cutoffs, a clear impact of maternal supplementation on the prevalence of low serum retinol was found. This was 15% in the vitamin A group at age six months, as compared with 36% in the placebo group (p < .005). The prevalence of low vitamin A stores, assessed by relative dose response (RDR), was also significantly lower in the vitamin A group (10% vs 23%, p < .03).
The Bangladesh trial used <0.70 µmol/L as the serum retinol cutoff level, and the modified relative dose response (MRDR) rather than RDR to assess liver stores. Smaller impacts were observed for maternal vitamin A supplementation than in the Indonesia trial (table 2); the differences did not reach statistical significance. The β-carotene group showed a marginally and nonsignificantly lower prevalence of low liver stores, but a higher prevalence of low serum retinol.
The multicenter study combined maternal and immunization-linked supplementation. It therefore does not provide an independent assessment of the impact of maternal supplementation on the infant's vitamin A status. The combined impact is discussed below. 
Impact on infant health
No trial has been identified that provides data on the impact of maternal supplementation shortly after delivery on infant morbidity and mortality.
Benefi ts of infant supplementation

Supplementation of newborns: Impact on morbidity and mortality
To date just one trial has been conducted in which vitamin A supplementation focused on newborns [5] (table 1). A group of 2,067 neonates was randomized to receive either 50,000 IU of vitamin A or a placebo on their first day of life. The infants were followed up at one year of age to determine the impact of the intervention on infant mortality. Outcome was confirmed for 89% of infants. Overall there were 19 deaths in the placebo group and 7 in the vitamin A group, yielding a relative risk of 0.36 with a 95% confidence interval from 0.16 to 0.87. This is equivalent to a 64% reduction in mortality, with a 95% confidence interval from 13% to 84%.
A substantial impact was clearly demonstrated. Examination of the survival curves, reproduced here in figure 2 , shows that all of the reduction occurred in the first five months of life; there were no deaths after this.
A subsample of 470 infants underwent a more intensive follow-up, with morbidity questionnaires administered at 4, 6, and 12 months. One-week period prevalences of common morbidities among the infants in this subsample showed no significant differences between the vitamin A and placebo groups at 4, 6, or 12 months. However, between birth and age 4 months, significantly fewer infants in the vitamin A group were taken for medical care for cough (14.2% vs 24.6%, p = .008) and fever (13.7% vs 20.7%, p = .063). There were no differences between treatment groups in the proportion of infants seeking treatment for diarrhea, difficult breathing, ear infection or pilek (a local term referring to upper respiratory tract symptoms such as runny nose) [5] . Between 4 and 6 months and between 6 and 12 months of age, there were no differences between groups in care-seeking for any diagnosis.
Periodic supplementation of young infants: Impact on mortality
A metaanalysis [8] carried out to ascertain the impact of vitamin A supplementation on childhood pneumonia also included an analysis of the impact of vitamin A supplementation on all-cause mortality in the first and second six months of life. The results are reproduced in table 4. The mortality reduction of 31% for the 6-to 11-month age group (RR = 0.69; 95% CI, 54-0.90 CI) was consistent with that reported for older children in the metaanalysis conducted by Beaton et al. [2] . However, no reduction was observed for the 0-to 5-month age group.
Two of the large-scale field trials of periodic supplementation of young children provided sufficient data on the mortality impact of periodic supplementation of young infants in both of these age periods. These are the Sarlahi [6] and Jumla [7, 8] trials in Nepal. The results are summarized in table 1. In the Sarlahi study, infants recruited into the study at one of the regular four-monthly home visits were given 50,000 IU of vitamin A if they were less than 1 month old and 100,000 IU if they were aged 1 to 5 months, the same dose that was given to infants aged 6 to 11 months. The Jumla study recruited children from 1 month of age; infants were also given 100,000 IU of vitamin A. Both showed an impact in the second 6 months of life but not the first (table 4) .
The vast majority of the data available for periodic supplementation of infants derive from the Sarlahi study. Reproduced in table 5 is a detailed analysis carried out by the investigators [6] to assess the impact on mortality of age of dosing according to month of age in the first six months of life. The mortality rates compared are those during the four months following dosing. Thus the deaths, child-years of follow-up, and mortality rates given for infants aged, for example, two months at the time of dosing will be based on data for them from two months to six months. Note that this is in contrast to table 4, where deaths and follow-up are shown according to the time period in which they occurred, and not according to age of dosing. This analysis clearly shows no impact on subsequent fourmonth mortality of dosing infants in the first four months of life. The impact seen in older children starts to be apparent for doses given at five months of age. 
Immunization-linked supplements to young infants
The only data currently available to assess immunization-linked supplementation are from the WHO/CAH (Department of Child and Adolescent Health and Development) multicenter study [9] , which combined this with maternal supplementation.
Benefi ts of combined maternal and infant supplementation
As immunization programs have established a delivery system that reaches a large proportion of young children, linking vitamin A supplementation to these programs could be one mechanism to achieve extensive coverage in vitamin A-deficient populations. An informal consultation [10] was convened by WHO's Nutrition Unit and the Expanded Program on Immu-nisations (EPI) in 1992 to assess the role of using immunization contacts to combat vitamin A deficiency. This recommended, in association with the International Vitamin A Consultative Group (IVACG), delivery of 25,000 IU of vitamin A with each of the first DPT immunizations (scheduled around 6, 10, and 14 weeks) and with measles immunization around 9 months. Among populations in which breastfeeding is common and prolonged, the group also recommended one large 200,000-IU dose to the mother during the safe period of postpartum infertility (about 60 days). This particular schedule formed the basis of the WHO/CAH immunization-linked supplementation trial [9] . This was a multicenter study carried out in Ghana, India, and Peru. A total of 8,439 infants and their mothers were randomized to vitamin A or control groups. Infants in the control group received 100,000 IU at nine months at the time of their measles immunization. The main findings are summarized in table 1. The impact of the maternal supplementation component on the mother's breastmilk vitamin A content has been discussed above. Figure 3 shows that the combined maternal and immunization-linked supplementation schedule achieved a modest impact on the infants' vitamin A status at 6 months. However, this effect was no longer apparent at age 9 months, and at age 12 months it was comparable to that achieved with the single large dose of 100,000 IU given to infants in the control group at 9 months.
No significant differences between groups in mortality were observed. The mortality curves for the vitamin A and control groups were extremely close up to nine months of age ( fig. 4 ). The rate ratio to compare all deaths up to age nine months was close to 1 (RR = 0.96; 95% CI, 0.73-1.27). The mortality curves appear to diverge after 9 months, with mortality between 9 and 12 months higher in the control group. However, this divergence cannot be interpreted as a real difference in mortality between the two groups. First, the study was not designed to achieve a high precision in the between-group comparison of mortality rates, and the sample size was not sufficient to support subgroup analyses. Second, the overall mortality rates until age 12 months did not differ significantly between the two groups. Furthermore, subsequent surveillance in the Ghana site with periodic supplementation of 200,000 IU to older children found no difference in mortality rates at age two years.* Finally, the intervention had no effect on overall or severe morbidity (tables 6 and 7) or on anthropometry. At no visit did the mean weight differ by more than 0.05 kg between the two groups, or the mean length by more than 0.1 cm.
Summary and conclusions
Consideration of the above evidence suggests the following speculative summary and conclusions.
A single maternal dose of 200,000 IU or of 300,000 IU delivered shortly after delivery improves breastmilk vitamin A content, at least for six months. However, in many sites this intervention is unlikely to be sufficient to correct the underlying subclinical vitamin A deficiency in the mothers. For example, in Bangladesh at three months, although the percentage of mothers with low breastmilk vitamin A concentration was markedly reduced in the vitamin A group, at 57% it was still unacceptably high.
A single maternal dose of 200,000 IU or more taken shortly after delivery, either alone or in combination with immunization-linked small doses of 25,000 IU, has a demonstrable but limited impact on the infant's vitamin A status. Although there is some variation between sites, the impact at age six months and beyond is insufficient to make firm conclusions on the benefits of vitamin A supplementation during early infancy. A and control groups during the first nine months of life. In addition, no differences in morbidity or anthropometry were found. Analysis of data concerning the first year of life from the large-scale field trials of periodic vitamin A supplementation suggests that dosing the infant during the first four months of life, even with 100,000 IU of vitamin A, has no impact on subsequent mortality. This impact starts to become apparent when dosing takes place at five months of age.
A dramatic 64% reduction in mortality in the first five months of life was achieved in the Indonesia trial [3] , following administration of 50,000 IU of vitamin A to newborns on their first day of life. This finding is in marked contrast with that of the immunizationlinked multicenter trial and certainly needs to be substantiated. In summary, more evidence is needed to justify starting vitamin A supplementation any earlier in infancy than five months.
Given the potential for wide coverage that would be afforded by linking vitamin A supplementation to immunization programs, this further suggests that the possibility of giving 100,000 IU alongside the third DPT vaccine should be explored. Several countries have recommended schedules in which the third DPT is given at five months. Even in countries where there are opportunities earlier (say at 14 weeks), natural delays will mean that a large proportion of children are likely to actually receive this dose closer to five months.
In order to consider what might be optimal linkages between vitamin A supplementation and immunization schedules, data concerning the actual age patterns of immunization contacts need to be considered in conjunction with recommended vitamin schedules. It is important both to ascertain the likely coverage with possible linking schedules and to assess the risks to children of receiving too frequent high doses. A close watch should be kept on the Zvitambo* trial in Zimbabwe. This trial started in 1998 and is due to be completed in 2002. It will recruit 14,000 mothers and their infants delivered at one of seven recruitment sites in greater Harare. They will be randomized into four treatment groups: 50,000 IU of vitamin A given to the neonate; 400,000 IU of vitamin A given to the mother during the immediate postpartum period; a combination of maternal and neonatal doses; and a placebo group. To date, no mortality trials of vitamin A supplementation have been completed in areas with high HIV prevalence and high incidence of vertical (motherto-child) HIV transmission. It is possible that early infant vitamin A supplementation may have a more important role in HIV endemic areas and that different vitamin A supplementation approaches need to be developed. A substudy of the Zvitambo trial is designed to evaluate in detail the impact of vitamin A supplements to the mother and/or child at birth on vertical HIV transmission during lactation, and on horizontal HIV transmission to HIV seronegative women during the immediate postpartum period.
